A study using Parkinson's disease animal model, transgenic fruit flies, demonstrated the
potential of using tocotrienols (HOV-12020) as a therapeutic agent for delaying Parkinsonian
motor dysfunctions. The proposed study aims to enrol 100 PD patients in a randomized
placebo-controlled trial to investigate the effects of tocotrienols (HOV-12020) in motor and
non-motor outcomes. Patients will be given oral tocotrienols (400mg/day) or placebo for 104
weeks. They will be assessed using the standard assessments scales in PD at baseline, Week 52
and Week 104. Neuropsychological evaluation will also be completed at these intervals to
monitor progression of cognitive impairment (if any). Additional PD staging using MDSUPDRS
(Part III), Hoehn & Yahr (H&Y) will be conducted at Week 26 and week 78. Blood samples will
be collected to evaluate PD biomarkers and for safety monitoring (liver function, renal
function and hematology).